YayaNews LogoYaya Financial News
美股Neutral$ABBV

AbbVie extends slide to a seventh straight session (ABBV:NYSE)

AbbVie stock dips after EPS guidance cut; EU expands Tepkinly label and Apogee deal adds upside.

Financial news writer0 ViewsSource Seeking Alpha

YayaNews contributes financial news and market context through the YayaNews editorial workflow.

AbbVie extends slide to a seventh straight session (ABBV:NYSE)
Image Source: Seeking Alpha

AbbVie stock dips after EPS guidance cut; EU expands Tepkinly label and Apogee deal adds upside.

AbbVie extends slide to a seventh straight session (ABBV:NYSE) | Seeking Alpha

Save

Play

(

2min

)

Comments

AbbVie (

ABBV

) declines 1.30% to $244.78 in Tuesday afternoon trading, on track for its seventh straight session of losses.

Over the past six trading sessions, the stock has declined 5.1%, compared with a 0.44% gain for the broader S&P 500 index. Year to date, AbbVie

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.

Is this happening to you frequently? Please

report it on our feedback forum.

If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.

Search field

Entering text into the input field will update the search result below

Entering text into the input field will update the search result below

Recommended For You

More

Trending News

See More

»

Disclaimer

Original YayaNews editorial coverage, published for informational purposes.

This article is sourced from Seeking Alpha. It is for informational purposes only and does not constitute investment advice.

Share

Topics & Symbols

Topics & symbols

Continue Reading

Previous & next

Related Reading

Go to Channel